Home / Health / Global HIV Fight Undermined by Aid Cuts
Global HIV Fight Undermined by Aid Cuts
31 Jul
Summary
- Injectable PrEP offers hope but faces severe funding reductions.
- US foreign aid cuts hinder access to vital HIV prevention.
- Experts warn of inability to meet 2030 AIDS elimination goal.
New injectable HIV prevention medication, lenacapavir, offers a promising advancement with its requirement for only two annual doses. This innovation could be a game-changer for individuals facing barriers to consistent medication access, such as those in poverty, experiencing stigma, or living in remote areas.
A mathematical modeling study estimated that widespread availability of lenacapavir could prevent 41% of new HIV infections in South Africa, Zimbabwe, and western Kenya. Despite this potential, experts at the Aids 2026 Conference in Rio de Janeiro highlighted a dramatic decline in global HIV prevention investment.
This decline is linked to major funding cuts, including the dissolution of USAID, which previously provided substantial resources for HIV prevention. These cuts impact not only the availability of new medications but also the crucial outreach services provided by peer workers, essential for engaging high-risk populations like people who inject drugs.
Furthermore, some pharmaceutical companies are excluding upper-middle-income countries from affordable medication agreements, despite these nations' contributions to clinical trials. This situation leads experts to believe that achieving the UNAIDS goal of eliminating AIDS as a public health threat by 2030 will be exceedingly difficult under the current funding landscape.
